Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The firm is also working on expanding its CTC capture capabilities beyond epithelial cells and will present multiple myeloma applications at an upcoming conference.
Although other groups have been developing noninvasive prenatal testing using digital PCR, BioCore claims to be the first to offer a test commercially.
Anitoa's handheld Maverick platform weighs one kilogram and comes with cloud-based analysis software.
The proposed diagnostic platform will be able to identify and determine resistance of bloodstream infections within three hours.
The quantitative paper-based DNA reader (qPDR) takes advantage of a recently discovered interaction between SYBR Green I and cellulose paper.
The Salt Lake City-based firm expects to launch a test in the infertility space this year and is also involved in endometriosis therapeutics development.
The Biomedical Advanced Research and Development Authority aims to produce at least two US Food and Drug Administration-cleared tests.
The new instrument has higher throughput than competing systems, while the flu test boasts enhanced sensitivity and protection against seasonal drift.
The lab will launch a carrier screening test this year, and plans to bring infectious disease, allergy, cognitive health, and toxicology tests as well.
The Global Virome Project proposes to discover all viruses capable of jumping between animals and humans, at an estimated cost of around $5 billion.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.